Login / Signup

A case of double-negative prostate cancer with BRCA2 mutation and high tumor mutation burden treated sequentially with olaparib and pembrolizumab.

Hiroki TanakaSoichiro YoshidaSatoru AoyamaSadakatsu IkedaJunko KuniedaKenichi OhashiShohei FukudaYuma WasedaHajime TanakaYasuhisa Fujii
Published in: IJU case reports (2024)
mutations and high tumor mutation burden.
Keyphrases
  • prostate cancer
  • radical prostatectomy
  • risk factors